Teneligliptin HydrobromideThird Party Manufacturing in India

Teneligliptin is a potent, long-acting dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control in patients with type 2 diabetes mellitus. DPP-4 is an enzyme that rapidly degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretins are released from intestinal L-cells and K-cells after food intake and play a critical role in glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells while suppressing glucagon release from alpha-cells, both in a strictly glucose-dependent manner.

By selectively inhibiting DPP-4, teneligliptin increases the circulating half-life and bioavailability of endogenous GLP-1 and GIP. The elevated GLP-1 levels enhance glucose-stimulated insulin secretion from the pancreas, meaning insulin is released only when blood glucose levels are elevated, which significantly reduces the risk of hypoglycemia compared to other antidiabetic agents. Simultaneously, the suppression of glucagon secretion reduces hepatic glucose production, contributing to lower both fasting and postprandial plasma glucose levels.

Teneligliptin is distinguished by its unique prolylthiazolidine structure, which gives it a strong and sustained binding affinity to the DPP-4 enzyme lasting more than 24 hours. This pharmacokinetic profile supports convenient once-daily dosing and provides consistent 24-hour glycemic control. The drug is metabolized primarily via CYP3A4 and FMO3 enzymes and demonstrates a low potential for clinically significant drug-drug interactions, making it well-suited for patients with type 2 diabetes who often require multiple concomitant medications.

Therapeutic Uses

Teneligliptin hydrobromide tablets are indicated for the management of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adult patients.

• Type 2 Diabetes Mellitus: Teneligliptin is used as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, or insulin when glycemic targets are not achieved with monotherapy alone. Its glucose-dependent mechanism of action provides effective HbA1c reduction with a low risk of hypoglycemia and a neutral effect on body weight.
• Postprandial Hyperglycemia: Teneligliptin is particularly effective at controlling postprandial glucose excursions due to its incretin-based mechanism. By increasing GLP-1 levels after meals, it directly addresses the postprandial hyperglycemia that contributes significantly to overall glycemic burden in type 2 diabetes.
• Combination Therapy: Teneligliptin 20 mg tablets are commonly used in fixed-dose combinations with other oral hypoglycemic agents to achieve synergistic glycemic control while maintaining a favorable safety profile.

Why Manufacturers Choose Teneligliptin

Teneligliptin is a well-established DPP-4 inhibitor in the Indian pharmaceutical market and is manufactured in two standard strengths: 10 mg and 20 mg tablets. Indian pharmaceutical companies produce teneligliptin tablets for both the domestic market and export across Asia, Africa, and Latin America. The molecule is popular for third party manufacturing because of its stable formulation, proven efficacy, and competitive pricing.

Manufactured under WHO-GMP certified facilities, teneligliptin tablets are available in various packaging formats for PCD pharma franchise companies. The growing prevalence of type 2 diabetes in developing countries ensures sustained demand for affordable DPP-4 inhibitors. Teneligliptin offers manufacturers a cost-effective alternative to newer gliptins while maintaining comparable efficacy, making it a valuable addition to any antidiabetic product portfolio.